



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

February 25, 2008

Docket No. 03013569
Control No. 141395

License No. 29-17874-01

Deborah Zastocki
President and CEO
Chilton Memorial Hospital
97 West Parkway
Pompton Plains, NJ 07444

SUBJECT: CHILTON MEMORIAL HOSPITAL, LICENSE AMENDMENT, CONTROL NO.
141395

Dear Ms. Zastocki:

This refers to your license amendment request. Enclosed with this letter is the amended license adding Dr. Konlian.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select **Nuclear Materials; Medical, Academic, and Industrial Uses of Nuclear Material**; then **Regulations, Guidance, and Communications**. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 7:00 a.m. to 8:00 p.m. EST, Monday through Friday (except Federal holidays).

Thank you for your cooperation.

Sincerely,

Original signed by Penny Lanzisera

Penny Lanzisera
Senior Health Physicist
Medical Branch
Division of Nuclear Materials Safety

Enclosure:
Amendment No. 35

D. Zastocki
Chilton Memorial Hospital

2

cc:
Stuart Moses, M.D., Radiation Safety Officer

D. Zastocki
Chilton Memorial Hospital

3

DOCUMENT NAME: C:\FileNet\ML080570053.wpd

SUNSI Review Complete: PLanzisera

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	☒ N	DNMS/RI	☐	DNMS/RI	☐		☐
NAME	PLanzisera/PL							
DATE	2-25-08							

OFFICIAL RECORD COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Chilton Memorial Hospital 2. 97 West Parkway Pompton Plains, New Jersey 07444	In accordance with the letter dated November 28, 2007, 3. License number 29-17874-01 is amended in its entirety to read as follows: 4. Expiration date July 31, 2014 5. Docket No. 030-13569 Reference No.
--	--

- | | | |
|---|---|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
| A. Any byproduct material permitted by 10 CFR 35.100 | A. Any | A. As needed |
| B. Any byproduct material permitted by 10 CFR 35.200 | B. Any | B. As needed |
| C. Any byproduct material permitted by 10 CFR 35.300 | C. Any | C. 500 millicuries |
| D. Any byproduct material permitted by 10 CFR 35.400 | D. Sealed Sources (Amersham OncoSeed Model 6711 and EchoSeed Model 6733; Bebig Model I25.S06; Theragenics Corporation I-Seed Model 125.S06; Best Industries International Model 2301; Mills Biopharmaceutical Models I-125 SL and I-125 SH; and Bard Model STM1251) | D. 2.5 curies |
| E. Strontium-90 | E. Sealed source (Amersham Model SIA.20) | E. 55 millicuries |

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
29-17874-01Docket or Reference Number
030-13569

Amendment No. 35

- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
 E. Strontium-90 for ophthalmic radiotherapy permitted by 10 CFR 35.400.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 97 West Parkway, Pompton Plains, New Jersey.
11. The Radiation Safety Officer for this license is Stuart Moses, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Denise McFadden, M.D.	35.100; 35.200
Steven Richman, M.D.	35.100; 35.200; 35.300
Joel S. Cooperman, M.D.	35.100; 35.200; 35.300
Jair E. Leichter, M.D.	35.100; 35.200; 35.300
Stuart Moses, M.D.	35.100; 35.200; 35.300 except thyroid carcinoma
Sherry Fine, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies
Daniel Levy, M.D.	35.100; 35.200; 35.300 except thyroid carcinoma
David R. Greenblatt, M.D.	35.300; 35.400; Strontium-90 for ophthalmic radiotherapy
Patrick J. Hines, M.D.	35.100, 35.200, 35.300 except thyroid carcinoma
Dov Gorshein, M.D.	35.300, 35.400, Strontium-90 for ophthalmic radiotherapy
Michael Forbes-Wesson, M.D.	35.400, Strontium-90 for ophthalmic radiotherapy

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
29-17874-01Docket or Reference Number
030-13569

Amendment No. 35

Authorized UsersMaterial and Use

Dhirendra Nath Das, M.D.

35.100, 35.200, Oral administration of sodium iodide iodine-131 for imaging and localization studies

Krishna Duvvuri, M.D.

35.200, Oral administration of sodium iodide iodine-131 for imaging and localization studies

Stuart L. Siepser, M.D.

35.200, Oral administration of sodium iodide iodine-131 for imaging and localization studies

Mitchell Baruchin, M.D.

35.200, Oral administration of sodium iodide iodine-131 for imaging and localization studies

Michael E. Kelly, M.D.

35.200, Oral administration of sodium iodide iodine-131 for imaging and localization studies

Stewart A. Berkowitz, M.D.

35.400, Strontium-90 for ophthalmic radiotherapy

Emile Doss, M.D.

35.200, Oral administration of sodium iodide iodine-131 for imaging and localization studies

Robert J. Cole, M.D.

35.300 except Iodine-131, 35.400, Strontium-90 for ophthalmic radiotherapy

Steven Leffler, M.D.

35.100, 35.200

Perry S. Williams, M.D.

35.400, Strontium-90 for ophthalmic radiotherapy

Donna Konlian, M.D.

35.200

C. The following individuals are authorized medical physicists:

Material and Use

David S. Marsden, Ph.D.

Strontium-90 sealed source for calculation of the activity used to determine the treatment time for ophthalmic treatments.

Laszlo Berkovits, M.S..

Strontium-90 sealed source for calculation of the activity used to determine the treatment time for ophthalmic treatments.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
29-17874-01Docket or Reference Number
030-13569

Amendment No. 35

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated February 25, 2004 (ML040720672)
B. Letter dated October 31, 2007 (ML073120566)



For the U.S. Nuclear Regulatory Commission

Date February 25, 2008

By

Original signed by Penny Lanzisera

Penny Lanzisera
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406